Search

Your search keyword '"Hematologic malignancy"' showing total 2,654 results
Start Over Descriptor "Hematologic malignancy"
2,654 results on '"Hematologic malignancy"'

20. Evaluation of ClearLLab LS Screening Panel

Author

Institute of Hematology & Blood Diseases Hospital, China, The First Affiliated Hospital of Soochow University, The First Affiliated Hospital with Nanjing Medical University, and Tongji Hospital

Published
2024

31. Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Patients With Pneumonia: A Prospective Observational Study.

Author

Bergin, Stephen, Chemaly, Roy, Dadwal, Sanjeet, Hill, Joshua, Lee, Yeon, Haidar, Ghady, Luk, Alfred, Drelick, Alexander, Chin-Hong, Peter, Benamu, Esther, Khawaja, Fareed, Nanayakkara, Deepa, Papanicolaou, Genovefa, Small, Catherine, Barron, Michelle, Davis, Thomas, McClain, Micah, Maziarz, Eileen, Madut, Deng, Bedoya, Armando, Gilstrap, Daniel, Todd, Jamie, Barkauskas, Christina, Bigelow, Robert, Leimberger, Jeffrey, Tsalik, Ephraim, Wolf, Olivia, Mughar, Mona, Hollemon, Desiree, Duttagupta, Radha, Lupu, Daniel, Bercovici, Sivan, Perkins, Bradley, Blauwkamp, Timothy, Fowler, Vance, Holland, Thomas, and Fung, Monica

Subjects
bronchoscopy, hematologic malignancy, hematopoietic cell transplant, immunocompromised pneumonia, microbial cell-free DNA sequencing, Adult, Humans, Prospective Studies, Pneumonia, Sequence Analysis, DNA, Immunocompromised Host
Abstract

BACKGROUND: Pneumonia is a common cause of morbidity and mortality, yet a causative pathogen is identified in a minority of cases. Plasma microbial cell-free DNA sequencing may improve diagnostic yield in immunocompromised patients with pneumonia. METHODS: In this prospective, multicenter, observational study of immunocompromised adults undergoing bronchoscopy to establish a pneumonia etiology, plasma microbial cell-free DNA sequencing was compared to standardized usual care testing. Pneumonia etiology was adjudicated by a blinded independent committee. The primary outcome, additive diagnostic value, was assessed in the Per Protocol population (patients with complete testing results and no major protocol deviations) and defined as the percent of patients with an etiology of pneumonia exclusively identified by plasma microbial cell-free DNA sequencing. Clinical additive diagnostic value was assessed in the Per Protocol subgroup with negative usual care testing. RESULTS: Of 257 patients, 173 met Per Protocol criteria. A pneumonia etiology was identified by usual care in 52/173 (30.1%), plasma microbial cell-free DNA sequencing in 49/173 (28.3%) and the combination of both in 73/173 (42.2%) patients. Plasma microbial cell-free DNA sequencing exclusively identified an etiology of pneumonia in 21/173 patients (additive diagnostic value 12.1%, 95% confidence interval [CI], 7.7% to 18.0%, P < .001). In the Per Protocol subgroup with negative usual care testing, plasma microbial cell-free DNA sequencing identified a pneumonia etiology in 21/121 patients (clinical additive diagnostic value 17.4%, 95% CI, 11.1% to 25.3%). CONCLUSIONS: Non-invasive plasma microbial cell-free DNA sequencing significantly increased diagnostic yield in immunocompromised patients with pneumonia undergoing bronchoscopy and extensive microbiologic and molecular testing. CLINICAL TRIALS REGISTRATION: NCT04047719.

Published
2024

40. Early Detection and Screening of Hematological Malignancies - SANGUINE (SANGUINE)

Author

Tel Aviv University, FORSCHUNGSZENTRUM FUR MEDIZINTECHNIK UND BIOTECHNOLOGIE, UNIVERZITA PALACKEHO V OLOMOUCI, FAKULTNI NEMOCNICE OLOMOUC, Vilnius University Hospital Santaros Klinikos, PREDICTBY RESEARCH AND CONSULTING S.L., ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON, Tel Aviv Medical Center, and UAB ORIENTOS

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results